Diaphragm Pacing Therapy System Market

Diaphragm Pacing Therapy System Market is valued at USD 5.40 Million in 2020 and expected to reach USD 8.01 Million by 2027 with the CAGR of 5.8% over the forecast period.

Diaphragm Pacing Therapy System Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increasing prevalence of berating regulation associated disorders and growth in spending on research and development are some factors driving the growth of diaphragm pacing therapy system market. 

Scope of Diaphragm Pacing Therapy System Market-

Diaphragm pacing is the lightweight battery-powered system that electrically stimulates to diaphragm muscles and nerves. This enables diaphragm to contract so that air is pulled into lungs and helps patients to breathe in a more normal fashion. Diaphragm pacing involves fixing four electrodes into diaphragm muscle and a fifth electrode just below the skin near the other electrodes. The electrodes are then connected to an external stimulator to provide an ongoing electrical impulse to the electrodes, causing diaphragm to contract and helps in normal breathing. The diaphragm pacing therapy system (DPTS) use to reduce the dependency on mechanical ventilators and to improve breathing and improvement of speech in patients. Its other advantages include eliminate the time spend using a ventilator by helping to breathe and speak more naturally. Diaphragm pacing used as a rehabilitative tool for patients with pompe disease who are ventilator dependent. In case of spinal injury is used to regulate the normal berating by providing electrical stimulation. Moreover, diaphragm pacing has application in rhythmic of electrical impulses to the diaphragm to provide artificial ventilatory support in case of respiratory failure.

Diaphragm pacing therapy system market report is segmented based on product type, application and by regional & country level. Based upon product type, diaphragm pacing therapy system market is classified into external diaphragm pacemaker and diaphragm pacemaker. Based upon application, diaphragm pacing therapy system market is classified into SCI, ALS and other.

The regions covered in this diaphragm pacing therapy system market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of diaphragm pacing therapy system is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Diaphragm Pacing Therapy System Companies:

Avery Biomedical Devices, Lungpacer Medical, Inc, Synapse Biomedical, Atrotech

Click Here to know more about Companies

Lungpacer Medical Receives FDA Emergency Use Authorization for Novel, Non-implanted Device to Wean Patients Off Mechanical Ventilation During Covid Crisis

News: April 14, 2020, Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced that the FDA has approved the emergency use authorization for the use of the lungpacer diaphragm pacing therapy system (DPTS) to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure.  According to the FDA letter, patients at high risk of weaning failure include COVID-19 patients requiring ventilation and [other] patients being mechanically ventilated for other high-risk conditions including post-cardiac and post-thoracic surgical procedures and medical ICU patients requiring prolonged ventilation. The approval states that FDA has concluded that the Lungpacer DPTS may be effective at treating patients during COVID-19 by helping wean patients off ventilators in healthcare settings, thereby reducing their risks of prolonged mechanical ventilation and increasing the availability of ventilators during the COVID-19 pandemic. 

Diaphragm Pacing Therapy System Market Dynamics –

Rising prevalence of breathing associated disorders including spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS) creating huge demand of demand in breathing regulation are the factors which will boost the global diaphragm pacing therapy system market and expected to witness significant growth over the forecast period. For instance, as per the National Spinal Cord Injury Statistical Center, in 2018, around 17,700 new spinal cord injury cases are reported yearly in the U.S that account for 54 injuries every million population, furthermore, approximately 288,000 patients were living with spinal cord injuries in the U.S in 2018. Moreover, raising vehicular crashes, falls, accidents, sports/recreation activities, and other acts of violence reported upsurge in the SCI patient count and subsequently creating demand for diaphragm pacing therapy systems.

On the other flip, less awareness and less adoption rate among the patient across the world may restrain the growth of market. Nevertheless, the ongoing global COVID-19 pandemic resulted in upsurge demand for ventilation requirements and creating the demand for alternative needed during respiratory care in COVID positive patients. Additionally, favourable regulatory policies are helping to adoption of this therapy. For instance, in April 2020, Lungpacer Medical received the U.S. FDA EUA (emergency use authorization) approval for the diaphragm pacing therapy system to assist the weaning COVID patients. These systems are an alternative to the mechanical ventilator for patients with residual function in the lungs, diaphragm, and phrenic nerves.

Diaphragm Pacing Therapy System Market Regional Analysis –

North America is dominating the diaphragm pacing therapy system market owing to raising healthcare expenditure and disposable income among the region. Additionally, presence of key players in the region and increasing research and development spend of regional companies expected to add lucrative growth in the region. Moreover, increasing prevalence of breathing associated disorder and favourable government regulation helping regional companies to grow. For instance, as per the ALS Association report, around 5,000 U.S. citizens are diagnosed with ALS every year. This has created the huge demand for the DPTS market in the segment.

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to positive trends associated to the increasing R&D investments and technological advancement in healthcare sectors. In addition, increasing per capital income in last few years expected to bolster the market growth.

  Report Coverage

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 5.40 Million
Base year considered	2020
Forecast Period CAGR %:	5.80 %
Market Size Expected in 2027:	USD 8.01 Million
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Avery Biomedical Devices, Lungpacer Medical, Inc, Synapse Biomedical, Atrotech
Segments Covered	By Product Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Diaphragm Pacing Therapy System Market Reports –

Global Market report covers in depth historical and forecast analysis.

Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Market report helps to identify opportunities in market place.

Global Market report covers extensive analysis of emerging trends and competitive landscape.

Diaphragm Pacing Therapy System Market Segmentation –

By Product Type: External Diaphragm Pacemaker, Diaphragm Pacemaker

By Applications: - SCI, ALS, Other

Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa.